Pfizer Inc. (PFE) Reportedly In Talks To Expand Plant In Lee County
Reports allege that Pfizer Inc. (NYSE:PFE) is holding talks with Lee County officials as it considers investing $100 million to expand a plant located in Sanford.
Posts Tagged ‘Is PFE A Good Stock To Buy Right Now?’
FDA Endorses 3 New Drug Applications (NDAs) From Merck & Co., Inc. (MRK), Pfizer Inc. (PFE)
The U.S. Food and Drug Administration (FDA) has acknowledged the filing for review of three New Drug Applications (NDAs) from Merck & Co., Inc. (NYSE:MRK) and Pfizer Inc.
Results In For Pfizer Inc. (PFE) Rheumatoid Arthritis Study
Results for the Pfizer Inc.
Pfizer Inc. (PFE) Invest For Attractive Valuation And The 4% Dividend Yield
Pfizer Inc. (NYSE:PFE) is one of the world’s largest pharmaceutical firms with sales exceeding $50 billion.
Manufacturing Delay Of Generic Drug From Pfizer Inc. (PFE) A Relief For Teva Pharmaceutical Industries Ltd (ADR) (TEVA)
Pfizer Inc. (NYSE:PFE) has been slapped with a warning letter by the Food and Drug Administration in regards to one of its fill/finish factories.
Three Stocks To Buy For Valentines Day
I’ll start with LVMH Moet Hennessy Louis Vuitton SE (ADR) (OTCMKTS:LVMUY), the world’s largest fashion powerhouse… and also happens to be the maker of fine champagne.
Pfizer Inc. (PFE) And Citibank To Work Together On $5 Billion Share Repurchase Program
Pfizer Inc. (NYSE:PFE) and Citibank have agreed to work together in the acceleration of share repurchase, which will involve buying back of Pfizer’s common stock.
Pfizer Inc. (PFE)’s Breast Cancer Drug Too Expensive: Says NICE
The National Institute for Health and Care Excellence (NICE) has declared the latest breast cancer drug too expensive to justify its use.
Double Down On Dividends With These 2 Covered Calls
Investor sell or write a call options over stocks they own in exchange for collecting a premium.
Pfizer Inc. (PFE) Challenges Businessmen To Come Up With Breast Cancer Solutions
Pfizer Inc. (NYSE:PFE) is stepping up its battle against breast cancer.
Gilead Sciences, Inc. (GILD) Is A Hail Mary: 3 Better Stocks To Consider
After a strong 2015, health care stocks are leading the way lower in 2016. And it’s been an even uglier year for biotechnology company Gilead Sciences, Inc.
FDA Agrees To Review IBRANCE (palbociclib) From Pfizer Inc. (PFE)
The U.S. Food and Drug Administration (FDA) has agreed to review a supplemental New Drug Application (sNDA) of CDK 4/6 inhibitor, IBRANCE (palbociclib) from Pfizer Inc.
Bristol-Myers Squibb Co (BMY) And Pfizer Inc. (PFE) Agree To $50 Million Loan To Portola Pharmaceuticals Inc (PTLA)
There is a need for additional funding towards the development and clinical studies of AndexXa, a new compound that is a prospective antidote for Factor Xa inhibitors.
Pfizer Inc. (PFE) Signs Agreement With NCI To Explore Immunotherapy
Pfizer Inc. (NYSE:PFE) has confirmed its collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), on immunotherapy development.
Pfizer Inc. (PFE) To Close 2 Britain Facilities, To Present New Xeljanz Data
Pfizer Inc. (NYSE:PFE) has recently revealed that it is closing two manufacturing plants in Britain.
Novartis AG (ADR) (NVS) And Pfizer Inc. (PFE) Are In A Race To Gain Favor In Breast Cancer
Novartis AG (ADR) (NYSE:NVS) CDK4/6 breast cancer drug remains on track with Pfizer Inc. (NYSE:PFE)'s Ibrance.
Pfizer Inc. (PFE): Safe And Steady Dividends
Pfizer was incorporated in 1942 and today is a global biopharmaceutical company with operations all across the globe.
Inside the FDA: Why The Pfizer, Inc. (PFE) Boxed Warning On Chantix Is Unlikely To Be Removed
On September 14, the Food and Drug Administration released two briefing documents for the joint meeting of two committees.
Pfizer Inc. (PFE) Troxyca ER Receives FDA Panel Approval
Pfizer Inc. (NYSE:PFE) painkiller drug Troxyca ER has received the backing of an FDA advisory panel for marketing approval.
Pfizer And Merck Earnings Previews: Mega-Cap Pharmas Try To Stem Revenue Erosion
This article is temporarily removed from Insider Monkey.
